Rezolute Inc
Change company Symbol lookup
Select an option...
RZLT Rezolute Inc
ALT Altimmune Inc
BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs
SGFY Signify Health Inc
FRC First Republic Bank
BACK IMAC Holdings Inc
LYLT Loyalty Ventures Inc
BOXD Boxed Inc
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Price
Delayed
$2.01
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 100 shares is on pace to be much lighter than RZLT's 10-day average volume of 34,584 shares.

100
Historical quotes & splits

Burlington Stores Q3 same-store sales down 17%; FactSet consensus down 16.6%

6:49 am ET November 22, 2022 (MarketWatch)
Print

(END) Dow Jones Newswires

November 22, 2022 06:49 ET (11:49 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure